DIAGNOS Successfully Completes ISO / MDSAP Audit
February 10 2022 - 10:14AM
Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture:
ADK) (OTCQB: DGNOF) a leader in early detection of critical health
issues through the use of its FLAIRE platform based on Artificial
Intelligence (AI), announces today that its quality management
system continues to comply with the ISO 13485 standard and
applicable regulatory requirements for medical devices.
As part of the requirements for the
commercialization of our flagship product CARA from Health Canada
and the Food and Drug Agency in the US (FDA), DIAGNOS must
undergo thorough statutory annual quality compliance
audits under the Medical Device Single Audit Program (MDSAP). MDSAP
is a comprehensive approach to quality management systems auditing
among countries devoted to enhance the safety of medical
devices.
“I would like to take this opportunity to thank
our employees for their hard work in this important process. Our
clients expect our healthcare solutions to perform in compliance
with the highest quality standards and DIAGNOS is able to meet
their expectations”, said Mr. André Larente, President of
DIAGNOS.
About DIAGNOS DIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based on its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s image enhancement algorithms provide sharper, clearer and
easier-to-analyze retinal images. CARA is a cost-effective tool for
real-time screening of large volumes of patients. CARA has been
cleared for commercialization by the following regulators: Health
Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA
(Saudi Arabia). Additional information is available at
www.diagnos.com and www.sedar.com. For further information, please
contact:
Mr. André Larente, President DIAGNOS Inc. Tel:
450-678-8882 ext. 224 alarente@diagnos.ca
This press release contains forward-looking
information. We cannot guarantee that the forward-looking
information mentioned will prove to be accurate, as there may be a
significant discrepancy between actual results or future events and
those mentioned in this statement. DIAGNOS disclaims any intention
or obligation to publicly update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise. The forward-looking information contained in this
press release is expressly covered by this caution.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024